Login to Your Account

Other News To Note

Friday, March 23, 2012
• ImmunoCellular Therapeutics Inc., of Woodland Hills, Calif., licensed intellectual property from the University of Pittsburgh covering EphA2, a tyrosine kinase receptor expressed by ovarian cancer and other advanced and metastatic malignancies.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription